Collaboration, License, Co-Promotion and Other Commercial Agreements - Summary (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Collaborative arrangements
Revenues:
Revenue	$ 63,086
Active pharmaceutical ingredient
Revenues:
Revenue	5,434
Collaborative arrangement, other agreements | Collaborative arrangements
Revenues:
Revenue	465
Calculated under Revenue Guidance in Effect before Topic 606 | Collaborative arrangements
Revenues:
Revenue		$ 51,865
Calculated under Revenue Guidance in Effect before Topic 606 | Active pharmaceutical ingredient
Revenues:
Revenue		12
Allergan | Collaborative arrangement, collaboration and license agreements | North America | Collaborative arrangements
Revenues:
Revenue	61,599
Allergan | Collaborative arrangement, collaboration and license agreements | Europe and Other | Collaborative arrangements
Revenues:
Revenue	272
Allergan | Collaborative arrangement, co-promotion agreements | Collaborative arrangements
Revenues:
Revenue	750
Allergan | Calculated under Revenue Guidance in Effect before Topic 606 | Collaborative arrangement, collaboration and license agreements | North America | Collaborative arrangements
Revenues:
Revenue		49,951
Allergan | Calculated under Revenue Guidance in Effect before Topic 606 | Collaborative arrangement, collaboration and license agreements | Europe and Other | Collaborative arrangements
Revenues:
Revenue		109
Allergan | Calculated under Revenue Guidance in Effect before Topic 606 | Collaborative arrangement, co-promotion agreements | Collaborative arrangements
Revenues:
Revenue		457
AstraZeneca | Collaborative arrangement | China, Hong Kong, and Macau | Collaborative arrangements
Revenues:
Revenue	0
AstraZeneca | Calculated under Revenue Guidance in Effect before Topic 606 | Collaborative arrangement | China, Hong Kong, and Macau | Collaborative arrangements
Revenues:
Revenue		208
Astellas Pharma Inc. | Japan | Active pharmaceutical ingredient
Revenues:
Revenue	$ 5,434
Astellas Pharma Inc. | Calculated under Revenue Guidance in Effect before Topic 606 | Japan | Active pharmaceutical ingredient
Revenues:
Revenue		12
Exact Sciences | Calculated under Revenue Guidance in Effect before Topic 606 | Collaborative arrangement, co-promotion agreements | Collaborative arrangements
Revenues:
Revenue		$ 1,140